Provided by Tiger Trade Technology Pte. Ltd.

Amgen

377.35
-5.1200-1.34%
Post-market: 377.950.6000+0.16%19:59 EDT
Volume:2.27M
Turnover:861.29M
Market Cap:203.20B
PE:23.44
High:386.99
Open:386.14
Low:377.22
Close:382.47
52wk High:447.03
52wk Low:269.77
Shares:538.48M
Float Shares:536.99M
Volume Ratio:0.68
T/O Rate:0.42%
Dividend:9.80
Dividend Rate:2.60%
EPS(TTM):16.10
EPS(LYR):14.23
ROE:91.47%
ROA:8.67%
PB:17.38
PE(LYR):26.52

Loading ...

US Equity Markets End Lower After Houthi Attack on Saudi Arabia Energy Facilities

MT Newswires Live
·
Sep 09

TD Cowen Keeps Their Buy Rating on Amgen (AMGN)

TIPRANKS
·
Sep 09

Amgen Stock Poised for Worst Day in More than Two Decades

Dow Jones
·
Sep 09

Top Midday Decliners

MT Newswires Live
·
Sep 09

U.S. Stocks on the MOVE-Best Buy, Peloton, Apple

Reuters
·
Sep 09

Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says

MT Newswires Live
·
Sep 09

Royalty Pharma Falls After Novartis' Cholesterol Drug Fails in Study

Reuters
·
Sep 09

Amgen Pulls Dow Industrials Lower; Oil Jumps on Houthi Strikes in Saudi Arabia

Dow Jones
·
Sep 09

Top Midday Stories: GE Aerospace to Acquire Consolidated Precision Products; Qualcomm Issues Share Warrant to Amazon

MT Newswires Live
·
Sep 08

NASDAQ Top and Bottom Performing Stocks at About 11:01 A.m. EDT on 2026-09-08

Reuters
·
Sep 08

Amgen Says Phase 3 Study Meets Primary Endpoint in Small Cell Lung Cancer

MT Newswires Live
·
Sep 08

Amgen Inc Stock (AMGN) Moved Down by 8.33% on Sep 8: A Full Analysis

TradingKey
·
Sep 08

U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis

Reuters
·
Sep 08

Dow Drops 438 Points on Losses for Amgen, Salesforce Shares

Dow Jones
·
Sep 08

Amgen Down Nearly 7%, on Pace for Largest Percent Decrease Since March 2020

Dow Jones
·
Sep 08

Movement Alert|Amgen Falls 6.48% in Regular Trading, Novartis Lp(a) Drug Phase III Failure Casts Shadow Over Shared Pipeline

Market Focus
·
Sep 08

Amgen-AstraZeneca Cancer Drug Combo Hits Main Survival Goal in Late-Stage Trial

Reuters
·
Sep 08

AstraZeneca announces results from Phase III trial of IMFINZI, tarlatamab

TIPRANKS
·
Sep 08

Amgen - Phase 3 Dellphi-305 Study Delivers Significant Overall Survival Benefit Versus Durvalumab Alone

THOMSON REUTERS
·
Sep 08

Imdelltra® in Combination with Imfinzi® Demonstrated Landmark Improvement in Overall Survival in First-Line Extensive Stage Small Cell Lung Cancer

THOMSON REUTERS
·
Sep 08